<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952614</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00007284</org_study_id>
    <secondary_id>7300</secondary_id>
    <nct_id>NCT00952614</nct_id>
  </id_info>
  <brief_title>A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion</brief_title>
  <official_title>A Pilot Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenn Jaffe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a fluocinolone sustained drug delivery
      implant is effective in the treatment of central retinal vein occlusion that has caused
      persistent macular edema and decreased visual acuity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently there is limited treatment for macular edema and vision loss due to central retinal
      vein occlusion. Case reports have shown some benefit of intravitreal steroid injections in
      improving vision and reducing macular edema in eyes with retinal vein occlusions.

      Recently, a sustained drug release steroid implant has been investigated and FDA approved to
      treat macular edema in patients with non-infectious uveitis, eye inflammation. This implant
      is placed through an incision in the eye wall and is designed to deliver a steroid,
      fluocinolone acetonide, for up to three years. In animal studies there was no detectable
      steroid seen in the blood stream.

      This pilot trial will recruit individuals who have had a central retinal vein occlusion in at
      least one eye. If the macular edema and vision improves with an initial intravitreal
      injection, the eye will be considered to receive the sustained drug release device. The
      dosage of fluocinolone acetonide used is 0.59 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts</measure>
    <time_frame>baseline (preoperatively) to 3 years postoperatively</time_frame>
    <description>Outcome measure based on eyes at time points with 10-letter ETDRS score improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Macular Edema on Optical Coherence Tomography and Color Photos</measure>
    <time_frame>baseline (preoperatively) to 3 years postoperatively</time_frame>
    <description>Anatomic Change in reading of the size of the area of retinal thickening on color photographs and OCT. Total Macular Volume (TMV) in mm^3, is the calculated volume from the layers of the retina based off OCT imaging.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Central Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Retisert for Retinal Vein Occlusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fluocinolone acetonide (Retisert Implant, Bausch and Lomb)</intervention_name>
    <description>sustained release device consisting of 0.59 mg of fluocinolone acetonide</description>
    <arm_group_label>Retisert for Retinal Vein Occlusion</arm_group_label>
    <other_name>Retisert Implant, Bausch and Lomb, Rochester, NY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are eligible to receive an implant if they met all the following criteria:

          -  A history of central retinal vein occlusion that had caused macular edema, based on
             clinical evaluation and demonstrated on fundus photography, fluorescein angiography,
             and optical coherence tomography (OCT)

          -  Macular edema at least one disc area in size that involved the fovea

          -  Males and non-pregnant females at least 18 years of age

          -  Intraocular Pressure (IOP) controlled at &lt; 21 mmHg with no more than one topical
             ocular antihypertensive agent

          -  Ability and willingness to comply with treatment and follow up process and to
             understand and sign the informed consent form.

          -  Initially, patients with central retinal vein occlusion were not required to have
             previous therapy. However, the protocol was subsequently modified to require an
             intravitreal injection of triamcinolone acetonide &gt; 12 weeks prior to study entry,
             with an initial decrease in macular edema and improvement in visual acuity and
             subsequent decline in visual acuity accompanied by increased macular edema. This
             modification was added to avoid enrolling patients who might have had a long-lasting
             response to a single intravitreal triamcinolone acetonide injection.

        Exclusion Criteria:

          -  Patients are excluded if they have an allergy to fluocinolone acetonide or any
             component of the delivery system, a peripheral retinal detachment in the area of
             implantation, or media opacity precluding evaluation of study eye status.

          -  Patents with disciform scars of the fovea or atrophic changes of the macula that in
             the investigator's opinion would preclude benefit from treatment are excluded from the
             study.

          -  Female patients who were pregnant or lactating or not taking precautions to avoid
             pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn J Jaffe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Eye Center, DUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>August 6, 2013</results_first_submitted>
  <results_first_submitted_qc>May 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2014</results_first_posted>
  <last_update_submitted>August 1, 2014</last_update_submitted>
  <last_update_submitted_qc>August 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Glenn Jaffe</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>retinal vein occlusion</keyword>
  <keyword>sustained drug delivery implant</keyword>
  <keyword>steroid</keyword>
  <keyword>macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluocinolone Acetonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Twenty nine (29) participants were consented, 30 eyes. Of the 29 consented, there were 23 subjects included in the data pool of which one subject had both eyes included in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Retisert for Retinal Vein Occlusion</title>
          <description>0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
fluocinolone acetonide (Retisert Implant, Bausch and Lomb) : sustained release device consisting of 0.59 mg of fluocinolone acetonide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Started Treatment</title>
              <participants_list>
                <participants group_id="P1" count="30">29 subjects signed consent; 1 agreed for both eyes to enroll. 30 eyes rec'd drug delivery implant</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23">3 subjects died from unrelated causes, 3 were lost to follow-up &amp; 1 had both eyes included in study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Twenty nine participants were consented. Of the 29 consented (30 eyes; one subject consented twice), 23 participants were studied and 24 eyes. Both eyes of one participant were studied</population>
      <group_list>
        <group group_id="B1">
          <title>Retisert for Retinal Vein Occlusion</title>
          <description>0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
fluocinolone acetonide (Retisert Implant, Bausch and Lomb) : sustained release device consisting of 0.59 mg of fluocinolone acetonide</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts</title>
        <description>Outcome measure based on eyes at time points with 10-letter ETDRS score improvement</description>
        <time_frame>baseline (preoperatively) to 3 years postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Retisert for Retinal Vein Occlusion</title>
            <description>0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
fluocinolone acetonide (Retisert Implant, Bausch and Lomb) : sustained release device consisting of 0.59 mg of fluocinolone acetonide
Measure visual acuity improvement from baseline to time periods of 1,2, and 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts</title>
          <description>Outcome measure based on eyes at time points with 10-letter ETDRS score improvement</description>
          <units>letters read correctly</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in ETDRS @ 1 year after implant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="6" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in ETDRS @ 2 years after implant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in ETDRS @ 3 years after implant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="9" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Macular Edema on Optical Coherence Tomography and Color Photos</title>
        <description>Anatomic Change in reading of the size of the area of retinal thickening on color photographs and OCT. Total Macular Volume (TMV) in mm^3, is the calculated volume from the layers of the retina based off OCT imaging.</description>
        <time_frame>baseline (preoperatively) to 3 years postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Retisert for Retinal Vein Occlusion</title>
            <description>0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
fluocinolone acetonide (Retisert Implant, Bausch and Lomb) : sustained release device consisting of 0.59 mg of fluocinolone acetonide</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Macular Edema on Optical Coherence Tomography and Color Photos</title>
          <description>Anatomic Change in reading of the size of the area of retinal thickening on color photographs and OCT. Total Macular Volume (TMV) in mm^3, is the calculated volume from the layers of the retina based off OCT imaging.</description>
          <units>improvement in TMV/mm^3</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="9.0" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Retisert for Retinal Vein Occlusion</title>
          <description>0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
fluocinolone acetonide (Retisert Implant, Bausch and Lomb) : sustained release device consisting of 0.59 mg of fluocinolone acetonide</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Unrelated to study activity. 29 subjects consented, 30 enrolled. 1 subject consented twice. Ocular AEs are based on 30 eyes.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <description>Developed 1 week after implant &amp; resolved. Retinal Detachment (RD) developed months later; implant was removed during RD repair.
29 subjects consented, 30 enrolled. 1 subject consented twice. Ocular AEs are based on 30 eyes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glenn J. Jaffe, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-4458</phone>
      <email>jaffe001@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

